Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avigan

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, et al.
American Journal of Hematology|August 19, 2014
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantationVincent T Ho, Haesook T Kim, Grace Kao, et al.
Blood|June 13, 2019
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Jon E Arnason, Ann S LaCasce, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Phase I trial of parathyroid hormone to facilitate stem cell mobilizationKaren K Ballen, Elizabeth J Shpall, David Avigan, et al.
Oncotarget|March 31, 2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsBurcu Yigit, Peter J Halibozek, Shih-Shih Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.
British Journal of Haematology|April 17, 2004
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myelomaNoopur Raje, Teru Hideshima, Faith E Davies, et al.
Cancer Immunology, Immunotherapy : CII|July 14, 2022
Personalized tumor vaccine for pancreatic cancerShira Orr, Ling Huang, James Moser, et al.
Molecular Cancer Therapeutics|July 22, 2017
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell LymphomaSalvia Jain, Abigail Washington, Rebecca Karp Leaf, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, et al.
American Journal of Hematology|August 19, 2014
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantationVincent T Ho, Haesook T Kim, Grace Kao, et al.
Blood|June 13, 2019
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Jon E Arnason, Ann S LaCasce, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Phase I trial of parathyroid hormone to facilitate stem cell mobilizationKaren K Ballen, Elizabeth J Shpall, David Avigan, et al.
Oncotarget|March 31, 2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsBurcu Yigit, Peter J Halibozek, Shih-Shih Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.
British Journal of Haematology|April 17, 2004
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myelomaNoopur Raje, Teru Hideshima, Faith E Davies, et al.
Cancer Immunology, Immunotherapy : CII|July 14, 2022
Personalized tumor vaccine for pancreatic cancerShira Orr, Ling Huang, James Moser, et al.
Molecular Cancer Therapeutics|July 22, 2017
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell LymphomaSalvia Jain, Abigail Washington, Rebecca Karp Leaf, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Pageof 12